Targeting prostate cancer with specialized CAR-T cells
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10898319
This study is testing a new type of CAR-T cell therapy for men with neuroendocrine prostate cancer, aiming to create a treatment that can better target the cancer as it changes, using special cells that can find and attack the tumors more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10898319 on ClinicalTrials.gov |
What this research studies
This research aims to develop a new type of CAR-T cell therapy specifically designed to target neuroendocrine prostate cancer (NEPC), which often shows varied antigen expression. The approach focuses on using bi-specific CAR-T cells that can recognize both DLL3 and PSMA antigens, which change as the cancer progresses. By utilizing advanced imaging techniques, the therapy seeks to effectively deliver these CAR-T cells to the cancer sites, ensuring they can survive and function properly in the challenging environment of metastatic tumors. The research builds on previous successes in treating blood cancers and aims to adapt these strategies for solid tumors like NEPC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with neuroendocrine prostate cancer, particularly those with castrate-resistant disease.
Not a fit: Patients with other types of prostate cancer or those who do not express the targeted antigens DLL3 and PSMA may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with neuroendocrine prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results using CAR-T cell therapies in hematologic malignancies, but this approach for solid tumors like NEPC is still being explored.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PONOMAREV, VLADIMIR — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: PONOMAREV, VLADIMIR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.